Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Lorenza Rimassa, ESMO 2019 – COSMIC-312 study in hepatocellular carcinoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 8th 2019

We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma.

Questions
1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05)
2. What is the rationale for combining cabozantinib with atezolizumab in this treatment setting? (0:54)
3. Could you tell us a little about the aims and design of the COSMIC-312 study? (1:41)
4. When are results expected from this study? (2:34)
5. What other combined immunotherapy approaches seem promising? (2:56)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Lorenza Rimassa has received lecture fees from AstraZeneca, AbbVie, Gilead, Roche; Advisory board/consulting role fees from Lilly, Bayer, Sirtex Medical, ArQule, Exelixis, Ipsen, Celgene, Eisai, Hengrui Therapeutics, MSD, Baxter, Amgen, Italfarmaco, Sanofi, Incyte; Travel expenses from ArQule and Ipsen.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup